Literature DB >> 20977938

Migraine preventive drugs differentially affect cortical spreading depression in rat.

Volodymyr Borysovych Bogdanov1, Sylvie Multon, Virginie Chauvel, Olena Viktorivna Bogdanova, Dimiter Prodanov, Mykola Yukhymovych Makarchuk, Jean Schoenen.   

Abstract

Cortical spreading depression (CSD) is the most likely cause of the migraine aura. Drugs with distinct pharmacological properties are effective in the preventive treatment of migraine. To test the hypothesis that their common denominator might be suppression of CSD we studied in rats the effect of three drugs used in migraine prevention: lamotrigine which is selectively effective on the aura but not on the headache, valproate and riboflavin which have a non-selective effect. Rats received for 4 weeks daily intraperitoneal injections of one of the three drugs. For valproate and riboflavin we used saline as control, for lamotrigine its vehicle dimethyl sulfoxide. After treatment, cortical spreading depressions were elicited for 2h by occipital KCl application. We measured CSD frequency, its propagation between a posterior (parieto-occipital) and an anterior (frontal) electrode, and number of Fos-immunoreactive nuclei in frontal cortex. Lamotrigine suppressed CSDs by 37% and 60% at posterior and anterior electrodes. Valproate had no effect on posterior CSDs, but reduced anterior ones by 32% and slowed propagation velocity. Riboflavin had no significant effect at neither recording site. Frontal Fos expression was decreased after lamotrigine and valproate, but not after riboflavin. Serum levels of administered drugs were within the range of those usually effective in patients. Our study shows that preventive anti-migraine drugs have differential effects on CSD. Lamotrigine has a marked suppressive effect which correlates with its rather selective action on the migraine aura. Valproate and riboflavin have no effect on the triggering of CSD, although they are effective in migraine without aura. Taken together, these results are compatible with a causal role of CSD in migraine with aura, but not in migraine without aura. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20977938     DOI: 10.1016/j.nbd.2010.10.014

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  28 in total

Review 1.  Pathophysiology of medication-overuse headache: implications from animal studies.

Authors:  Saknan Bongsebandhu-phubhakdi; Anan Srikiatkhachorn
Journal:  Curr Pain Headache Rep       Date:  2012-02

2.  The effects of acute and preventive migraine therapies in a mouse model of chronic migraine.

Authors:  Alycia F Tipton; Igal Tarash; Brenna McGuire; Andrew Charles; Amynah A Pradhan
Journal:  Cephalalgia       Date:  2016-07-19       Impact factor: 6.292

3.  Potentiation of spontaneous and evoked cortical electrical activity after spreading depression: in vivo analysis in well-nourished and malnourished rats.

Authors:  Thays Kallyne Marinho de Souza; Mariana Barros e Silva; André Ricardson Gomes; Hélio Magalhães de Oliveira; Renato Barros Moraes; Catão Temístocles de Freitas Barbosa; Rubem Carlos Araújo Guedes
Journal:  Exp Brain Res       Date:  2011-08-24       Impact factor: 1.972

Review 4.  Pharmacological targeting of spreading depression in migraine.

Authors:  Katharina Eikermann-Haerter; Anil Can; Cenk Ayata
Journal:  Expert Rev Neurother       Date:  2012-03       Impact factor: 4.618

Review 5.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

Review 6.  Migraine with prolonged aura: phenotype and treatment.

Authors:  Michele Viana; Shazia Afridi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-11-16       Impact factor: 3.000

Review 7.  Cortical spreading depression and migraine.

Authors:  Andrew C Charles; Serapio M Baca
Journal:  Nat Rev Neurol       Date:  2013-09-17       Impact factor: 42.937

8.  Heterogeneous incidence and propagation of spreading depolarizations.

Authors:  Dan Kaufmann; Jeremy J Theriot; Jekaterina Zyuzin; C Austin Service; Joshua C Chang; Y Tanye Tang; Vladimir B Bogdanov; Sylvie Multon; Jean Schoenen; Y Sungtaek Ju; K C Brennan
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

9.  δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.

Authors:  Amynah A Pradhan; Monique L Smith; Jekaterina Zyuzin; Andrew Charles
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 10.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.